Drug intelligence / Profile preview

RR-M04

Development stage: Preclinical
Lead developer: RocRock Biotechnology
Modality: CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies

Overview

RR-M04 is an experimental Chimeric Antigen Receptor Macrophage (CAR-M) cell therapy being developed by RocRock Biotechnology for the treatment of prostate cancer. As a CAR-M therapy, it involves engineering macrophages to express a chimeric antigen receptor that recognizes specific markers on prostate cancer cells, potentially overcoming the immunosuppressive microenvironment of solid tumors. The specific antigen target for RR-M04 has not been publicly disclosed by the company. It is currently in the preclinical stage of development, specifically within the proof-of-concept or animal experiment phases.

Beyond the preview

Go deeper on RR-M04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RR-M04.

Explore the full profile